GMDA
Gamida Cell Ltd. · NASDAQ
Gamida Cell Ltd. (GMDA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for GMDA in the last 30 days. The most recent was published May 12, 2025.
Latest news
25 items- PRPurple Biotech Appoints Shai Lankry as Chief Financial OfficerU.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke
- PRHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr
- SECSEC Form EFFECT filed by Gamida Cell Ltd.EFFECT - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form EFFECT filed by Gamida Cell Ltd.EFFECT - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form EFFECT filed by Gamida Cell Ltd.EFFECT - Gamida Cell Ltd. (0001600847) (Filer)
- SECGamida Cell Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits (Amendment)8-K/A - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form S-8 POS filed by Gamida Cell Ltd.S-8 POS - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form S-8 POS filed by Gamida Cell Ltd.S-8 POS - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form S-8 POS filed by Gamida Cell Ltd.S-8 POS - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form POS AM filed by Gamida Cell Ltd.POS AM - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form POS AM filed by Gamida Cell Ltd.POS AM - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form POS AM filed by Gamida Cell Ltd.POS AM - Gamida Cell Ltd. (0001600847) (Filer)
- SECSEC Form 25-NSE filed by Gamida Cell Ltd.25-NSE - Gamida Cell Ltd. (0001600847) (Subject)
- SECGamida Cell Ltd. filed SEC Form 8-K: Bankruptcy or Receivership8-K - Gamida Cell Ltd. (0001600847) (Filer)
- SECGamida Cell Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits (Amendment)8-K/A - Gamida Cell Ltd. (0001600847) (Filer)
- PRXORTX Welcomes New Member to the Board of DirectorsCALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv
- SECGamida Cell Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits (Amendment)8-K/A - Gamida Cell Ltd. (0001600847) (Filer)
- NEWSWhy Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of Ulta Beauty, Inc. (NASDAQ:ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers ARCA biopharma, Inc. (NASDAQ:ABIO) climbed 108% to $3.5549 after the company and Oruka Therapeutics announced a merger agreement. Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares gained 89% to $0.1906 after the company entered a merger agreement with TuHURA Biosciences. Next Technology Holding Inc. (NASDAQ:NXTT) rose 57.4% to $6.42. Vanda Ph
- NEWSWhy Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving PremarketShares of Cal-Maine Foods, Inc. (NASDAQ:CALM) rose sharply in today’s pre-market trading after the company reported upbeat results for its fourth quarter. The company reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.46 per share, according to data from Benzinga Pro. Cal-Maine Foods shares jumped 8.3% to $63.80 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers LAMF Global Ventures Corp. I (NASDAQ:LGVC) rose 148.9% to $26.79 in pre-market trading. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd. Aesthetic Medical International Holdings
- 13D/GSEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)
- PRAquestive Therapeutics Strengthens Board of Directors with Experienced Biotech ExecutiveWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
- SECGamida Cell Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Amendment)8-K/A - Gamida Cell Ltd. (0001600847) (Filer)
- NEWSWhy Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionShares of Kodiak Sciences Inc. (NASDAQ:KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing o
- NEWSUS Stocks Flat; Initial Jobless Claims Fall To 210,000U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38. Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power' Leading and Lagging Sectors Real estate shares jumped by 0.7% on Thursday. In trading on Thursday, information technology shares fell by 0.2%. Top Headline U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000. Equities Trading
- NEWSWhy RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving PremarketShares of RH (NYSE:RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company said it sees full-year 2024 demand growth of 12% to 14% and revenue growth of 8% to 10% on a year-over-year basis, according to data from Benzinga Pro. RH shares jumped 9.4% to $324.99 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Avalo Therapeutics, Inc. (NASDAQ:AVTX) rose 256.6% to $16.94 in pre-market trading after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisit
GMDA FAQ
8 questionsWhat does Gamida Cell Ltd. do?
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998...What is the latest news on GMDA?
Quantisnow has not tracked any new filings, ratings or press releases for GMDA in the last 30 days. The most recent wire item was published on May 12, 2025.Where does GMDA stock trade?
Gamida Cell Ltd. (GMDA) is listed on NASDAQ.What sector and industry is GMDA in?
Gamida Cell Ltd. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Gamida Cell Ltd. go public?
Gamida Cell Ltd. (GMDA) completed its IPO in 2018.What are analysts saying about GMDA?
Gamida Cell Ltd. has had 3 recent analyst actions on file. The most recent action was from Needham: Buy with a $12.00 price target on 2021-11-16. Recent price targets range from $11.00 to $15.00.What companies are similar to GMDA?
Notable peers in the same industry include MRNA (Moderna Inc.), AMGN (Amgen Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare GMDA side-by-side with any of them on Quantisnow.How can I track GMDA on Quantisnow?
Quantisnow aggregates Gamida Cell Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GMDA to receive live email and push alerts on every new disclosure.